Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others; Application: Oncology, Cardiology, and Others; Source: Nuclear Reactors and Cyclotrons; End User: Hospitals, Academic & Research Institutes, and Others; and Approach: Targeted Therapeutic [Rx] and Companion Diagnostic [DX])- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2021-2027

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Radiopharmaceutical Theranostics Market, By Radioisotope

7.1.  Radiopharmaceutical Theranostics Market, By Radioisotope, 2021-2027

7.1.1.     Technetium-99           

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Technetium-99

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Iodine-131

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     18F

7.1.4.1.          Market Revenue and Forecast (2016-2027)

7.1.5.     Y-90

7.1.5.1.          Market Revenue and Forecast (2016-2027)

7.1.6.     Lutetium (Lu) 177

7.1.6.1.          Market Revenue and Forecast (2016-2027)

7.1.7.     Copper (Cu) 67

7.1.7.1.          Market Revenue and Forecast (2016-2027)

7.1.8.     Copper (Cu) 64

7.1.8.1.          Market Revenue and Forecast (2016-2027)

7.1.9.     Others

7.1.9.1.          Market Revenue and Forecast (2016-2027)

7.1.10.  Iodine-131

7.1.10.1.       Market Revenue and Forecast (2016-2027)

7.1.11.  Iodine-131

7.1.11.1.       Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Radiopharmaceutical Theranostics Market, By Application

8.1.  Radiopharmaceutical Theranostics Market, by Application, 2021-2027

8.1.1.     Oncology

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Cardiology

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Others

8.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Radiopharmaceutical Theranostics Market, By Source

9.1.  Radiopharmaceutical Theranostics Market, by Source, 2021-2027

9.1.1.     Nuclear Reactors

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Cyclotrons

9.1.2.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global Radiopharmaceutical Theranostics Market, By End User

10.1.          Radiopharmaceutical Theranostics Market, by End User, 2021-2027

10.1.1.  Hospitals

10.1.1.1.       Market Revenue and Forecast (2016-2027)

10.1.2.  Academic & Research Institutes

10.1.2.1.       Market Revenue and Forecast (2016-2027)

10.1.3.  Others

10.1.3.1.       Market Revenue and Forecast (2016-2027)

Chapter 11.Global Radiopharmaceutical Theranostics Market, By Approach

11.1.          Radiopharmaceutical Theranostics Market, by Approach, 2021-2027

11.1.1.  Targeted Therapeutic (Rx)

11.1.1.1.       Market Revenue and Forecast (2016-2027)

11.1.2.  Companion Diagnostic (DX)

11.1.2.1.       Market Revenue and Forecast (2016-2027)

Chapter 12.Global Radiopharmaceutical Theranostics Market, Regional Estimates and Trend Forecast

12.1.          North America

12.1.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.2.  Market Revenue and Forecast, by Application (2016-2027)

12.1.3.  Market Revenue and Forecast, by Source (2016-2027)

12.1.4.  Market Revenue and Forecast, by End User (2016-2027)

12.1.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.1.6.  U.S.

12.1.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.1.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.1.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.1.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.1.7.  Rest of North America

12.1.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.1.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.1.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.1.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.1.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.          Europe

12.2.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.2.  Market Revenue and Forecast, by Application (2016-2027)

12.2.3.  Market Revenue and Forecast, by Source (2016-2027)

12.2.4.  Market Revenue and Forecast, by End User (2016-2027)

12.2.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.2.6.  UK

12.2.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.7.  Germany

12.2.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.8.  France

12.2.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.2.9.  Rest of Europe

12.2.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.2.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.2.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.2.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.2.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.          APAC

12.3.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.2.  Market Revenue and Forecast, by Application (2016-2027)

12.3.3.  Market Revenue and Forecast, by Source (2016-2027)

12.3.4.  Market Revenue and Forecast, by End User (2016-2027)

12.3.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.3.6.  India

12.3.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.7.  China

12.3.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.8.  Japan

12.3.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.3.9.  Rest of APAC

12.3.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.3.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.3.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.3.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.3.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.          MEA

12.4.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.2.  Market Revenue and Forecast, by Application (2016-2027)

12.4.3.  Market Revenue and Forecast, by Source (2016-2027)

12.4.4.  Market Revenue and Forecast, by End User (2016-2027)

12.4.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.4.6.  GCC

12.4.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.7.  North Africa

12.4.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.8.  South Africa

12.4.8.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.8.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.8.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.8.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.8.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.4.9.  Rest of MEA

12.4.9.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.4.9.2.       Market Revenue and Forecast, by Application (2016-2027)

12.4.9.3.       Market Revenue and Forecast, by Source (2016-2027)

12.4.9.4.       Market Revenue and Forecast, by End User (2016-2027)

12.4.9.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.5.          Latin America

12.5.1.  Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.2.  Market Revenue and Forecast, by Application (2016-2027)

12.5.3.  Market Revenue and Forecast, by Source (2016-2027)

12.5.4.  Market Revenue and Forecast, by End User (2016-2027)

12.5.5.  Market Revenue and Forecast, by Approach (2016-2027)

12.5.6.  Brazil

12.5.6.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.6.2.       Market Revenue and Forecast, by Application (2016-2027)

12.5.6.3.       Market Revenue and Forecast, by Source (2016-2027)

12.5.6.4.       Market Revenue and Forecast, by End User (2016-2027)

12.5.6.5.       Market Revenue and Forecast, by Approach (2016-2027)

12.5.7.  Rest of LATAM

12.5.7.1.       Market Revenue and Forecast, By Radioisotope (2016-2027)

12.5.7.2.       Market Revenue and Forecast, by Application (2016-2027)

12.5.7.3.       Market Revenue and Forecast, by Source (2016-2027)

12.5.7.4.       Market Revenue and Forecast, by End User (2016-2027)

12.5.7.5.       Market Revenue and Forecast, by Approach (2016-2027)

Chapter 13.   Company Profiles

13.1.                 Nihon Medi-Physics

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.                 ITM Isotopen Technologien München AG

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.                 Advanced Accelerator Applications

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.                 Telix Pharmaceuticals

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.                 GE Healthcare

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.                 Theragnostics Ltd

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.                 NuView Life Sciences

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.                 Company 8

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.                 Jubilant Pharma Limited

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.              Lantheus Holdings, Inc.

13.10.1.                   Company Overview

13.10.2.                   Product Offerings

13.10.3.                   Financial Performance

13.10.4.                   Recent Initiatives

Chapter 14.   Research Methodology

14.1.                 Primary Research

14.2.                 Secondary Research

14.3.                 Assumptions

Chapter 15.   Appendix

15.1.                 About Us

15.2.                 Glossary of Terms